Clinical trial
The SLIM Study: Sling and Botox® Injection for Mixed Urinary Incontinence
Name
STU00201249
Description
This double-blind randomized controlled trial seeks to find a better treatment for women with mixed urinary incontinence (both stress and urgency incontinence). The primary aim is to determine whether midurethral sling surgery combined with injections of onabotulinumtoxinA (Botox®) into the detrusor muscle of the bladder improves symptoms of mixed urinary incontinence better than sling surgery alone.
Trial arms
Trial start
2016-02-01
Estimated PCD
2021-07-26
Trial end
2021-07-26
Status
Completed
Phase
Early phase I
Treatment
OnabotulinumtoxinA (Botox ®) Injections
OnabotulinumtoxinA (Botox ®) is a neurotoxin, which inhibits acetylcholine release and temporarily relaxes the bladder muscle to inhibit urgency incontinence.
Arms:
OnabotulinumtoxinA injections
Other names:
Botox ®
Saline Injections
Saline will be injected into the bladder so that investigators are masked to subject randomization.
Arms:
Saline injections
Size
100
Primary endpoint
Number of Participants With Self-reported Mixed Urinary Incontinence Symptoms
3 months after surgery
Eligibility criteria
Inclusion Criteria:
* Undergoing mid-urethral sling surgery
* Have symptoms of both stress and urgency urinary incontinence
* Able to consent, fill out study documents, and complete all study procedures and follow-up visits
* At least 18 years of age
* English speaking
* Be able and willing to learn clean intermittent self catheterization technique
Exclusion Criteria:
* History of recurrent UTI (defined as three culture proven UTIs within last 12 months)
* Systemic neuromuscular disease known to affect the lower urinary tract
* Undergoing concomitant prolapse surgery
* Previous incontinence surgery
* Treatment with anticholinergic medication in the last 2 months
* Previous bladder injection with onabotulinumtoxinA
* Prisoner Status
* Pregnancy
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE4'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 100, 'type': 'ACTUAL'}}
Updated at
2023-03-14
1 organization
2 products
3 indications
Organization
Northwestern UniversityProduct
OnabotulinumtoxinAIndication
Mixed Urinary IncontinenceIndication
urinary incontinenceIndication
Urge IncontinenceProduct
Saline